Galectin-3 levels in patients on immunotherapy for cancer
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study looks at a protein called galectin-3 in people with certain cancers who are getting immunotherapy (PD-1/PD-L1 inhibitors). It aims to see if galectin-3 levels can help predict how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have kidney cancer, bladder cancer, lung cancer, or liver cancer.
- You are about to start or are already receiving treatment with an immunotherapy drug called a PD-1 or PD-L1 inhibitor.
- You are not pregnant, not breastfeeding, and not planning to get pregnant (or for men, partner not planning to get pregnant) during the study.
- You can read and understand the consent form and are willing to follow all study requirements for the whole study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a blood/tissue marker called Glypican-3 to see who is more likely to do well when treated with immunotherapy for liver cancer. It may help doctors predict outcomes and tailor future care.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This study looks at how a drug called G-CSF affects certain immune cells and cancer stem cells in people with advanced lung cancer. The goal is to understand how these cells interact during chemotherapy and immunotherapy, which may help improve future treatments.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
Hear when a new Renal Cell Carcinoma (Kidney Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.